The Task Forces
Cancer Core Europe currently has several Task Forces working on different topics. These groups, which are made up of researchers, clinicians, biostatisticians, as well as imaging and IT specialists from all seven centers, will identify challenges, share best practices, harmonize procedures, form recommendations, and launch new common research projects. Ultimately, these efforts will inform ongoing and future translational and clinical research projects across Cancer Core Europe.
Concretely, Cancer Core Europe aims at creating a multi-site European Cancer Institute
carrying out joint translational and clinical research
conducting next-generation clinical trials
developing personalized cancer medicine
establishing standardized academic diagnostic platforms
creating large shared clinical & research databases along with efficient, easy to use tools for researchers, clinicians, and patients, including a clinical trials portal
performing outcomes research
Sharing data among all member institutes provides Cancer Core Europe’s researchers and clinicians with greater insight than any center could attain alone.
As more and more information is added to the data sharing platform, researchers should uncover trends that help them to predict which treatments work best, cost less, and have fewer side effects—just to provide a few examples of potential results.
Markers of response
Developing useful markers of response will help health care providers treat the right patients at the right time. Various types of markers can be envisaged. Molecular markers come from tumor DNA. Imaging technologies such as MRI or PET scans can be employed to visualize markers. Identifying particular features of individual’s immune systems could also potentially be used as a kind of marker.
Various types of markers can be envisaged. Molecular markers come from tumor DNA. Imaging technologies such as MRI or PET scans can be also addressed as disease markers. Identifying particular features of individual’s immune systems could also potentially be used as a kind of marker.
We believe that Cancer Core Europe can provide an effective platform to launch cutting-edge investigator-initiated clinical trials which will aim to greatly improve patient outcomes. Our clinical trials will benefit from simplified, coordinated procedures across Cancer Core Europe’s medical centers. Annually, the consortium sees 60,000 new patients, has 1.4 million outpatient visits, and provides 300,000 cancer treatments.
Training medical and research professionals
Working on developing cutting-edge therapies and diagnostics, Cancer Core Europe’s clinicians and researchers are eager to share their expertise and know-how. They will contribute to training medical and research professionals in the field of oncology through currently funded programs and as part of future projects, as well as disseminate their discoveries and healthcare advances to the public and specialists alike.
The consortium’s long-term objective is laying the foundation for an electronically-connected European Cancer Institute – starting with six centers of excellence, and now 7, we are building upon our core structure to expand and become an inclusive consortium uniting the whole of Europe.